Melanoma, Advanced Solid Tumours, Clear-Cell Renal-Cell Carcinoma (ccRCC) research hub

A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies

This study is testing a new drug (REGN10597) for cancers like melanoma and kidney cancer. It aims to see how safe it is, how well it's tolerated, and if it helps shrink tumours, either alone or with an existing treatment called Libtayo.